Skill Level 4
Relevance:4 Technical Level:2
Page Synopsis: particularly helpful with patients when there is evidence of viral activity
page 20 CFS > ALLOPATHIC MEDICINES > NEXAVIR KUTAPRESSIN
From: 'Chronic Fatigue Syndrome, A Roadmap for Testing and Treatment'
The injectable drug Nexavir formerly Kutapressin is an antiviral, an anti-inflammatory, and an immunomodulator that has demonstrated overall benefits for ME/CFS, and this drug is often employed by ME/CFS doctors, including Dr Cheney, Dr Enlander and Dr De Meirleir. Nexavir treatment protocols vary, but in one study, ME/CFS patients were given one subcutaneous 2 ml injection of Nexavir daily for the first 25 days of treatment; thereafter one injection every two days, for the next 50 days; and thereafter one injection three times a week for the next 105 days. This study reported a 42% remission rate in these patients at the end of this course of Nexavir treatment.1 http://www.ncf-net.org/library/kutreat.htm Each injection costs around $10. A low preservative version of Nexavir called 4ME is used by Dr Kenny De Meirleir. 4ME is available here http://www.kalidashop.com/en/4me.html.
Dr De Meirleir reports that around 70% of his ME/CFS patients experience at least a 20 point increase on the Karnofsky scale http://www.anapsid.org/cnd/diagnosis/karnofsky.html as a consequence of taking Nexavir.1
Dr Enlander says that Nexavir helps about 30% of his ME/CFS patients, and when combined with other compounds including vitamin B12 and glutathione injections, Dr Enlander reports Nexavir helps 67% of his ME/CFS patients.1
American Myalgic Encephalomyelitis and Chronic Fatigue Syndrome Society https://ammes.org/treatment/nexavir
Nexavir formerly Kutapressin is a peptide and amino acid solution derived from porcine pig liver. In the late 1920s, it was discovered that liver helped patients with acne vulgaris. As a result of this observation, attempts were made to isolate the active factor from liver. Not until the 1940s was a specially purified liver fraction isolated. Subsequent refinements in the isolation of the active material led to the development of what was then called Kutapressin, a biological as opposed to synthetic medication which had anti-inflammatory properties. Over the following decade, Kutapressin was used to treat a variety of dermatological conditions, including poison ivy, hives, eczema, and severe sunburn.
USES IN ME/CFS: Kutapressin's value as an ME/CFS treatment did not become generally known until Dr. Thomas Steinbach and Dr. William Hermann used Kutapressin successfully in the early 1980s to treat shingles and what was then referred to as Epstein-Barr virus reactivation CFIDS Chronicle, Summer 1990. Dr. Steinbach had observed that Kutapressin's antiviral and anti-inflammatory properties made it an effective treatment for infectious mononucleosis. Because of Kutapressin's excellent safety record and the positive results in treating Epstein-Barr virus infection, they conducted an informal unblinded study of some 270 patients with ME/CFS.
The results were impressive. Of the study participants, 75% showed improvement, and in some cases marked improvement, after only 40 injections of Kutapressin. Even more promising was that many of these patients had been ill with ME/CFS for more than five years.
A second study published by Dr. Steinbach and Dr. Hermann demonstrated the same impressive results presented at the International CFIDS Conference, Albany, N.Y., 1992. Of the 130 patients who participated in the second study, 85% reported notable or marked reduction of symptoms while receiving Kutapressin injections. Of 111 patients who reported significant reductions in symptoms, 103 noted results within six months of treatment. As a result of these studies, many ME/CFS clinicians began to incorporate Kutapressin in their treatment plans, particularly when there was evidence of viral activity high titers of human herpesvirus 6 and high interferon levels.
Some researchers have theorized that Kutapressin must have had both antiviral and immunomodulatory properties to simultaneously curtail viral reactivation and immune system upregulation. A study published by Dr. D.V. Ablashi and colleagues proved that Kutapressin was a potent inhibitor of herpesvirus 6 in vitro without causing cell damage In Vivo, 1994. A later study conducted in 1996 by Dr. E. Rosenfeld and colleagues found that Kutapressin was also effective against Epstein-Barr virus In Vivo, 1996. However, its role in immunomodulation remains speculative. Dr. Steinbach and Dr. Hermann postulated that Kutapressin may have acted to mediate the action of lymphokines, the immune system chemicals that are thought responsible for many of the symptoms characteristic of ME/CFS.
The ownership of Kutapressin has since changed hands. The distributor, Schwartz Pharma, sold Kutapressin, along with its client list, to Nexco Pharma, a Texas-based company. The product was renamed Nexavir, and while patients and doctors were assured that it was identical to the original formulation, this turned out not to be the case. Nexavir contains preservatives as well as tyrosine, an amino acid. Some doctors have switched to Hepapressin, a bovine liver alternative